Oxaliplatin As Part of Adjuvant Therapy for Colon Cancer: More Complicated Than Once Thought

被引：14
作者：
Mayer, Robert J. [1 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 27期
关键词：
PHASE-III TRIAL; FLUOROURACIL PLUS LEVAMISOLE; WEEKLY BOLUS FLUOROURACIL; DISEASE-FREE SURVIVAL; STAGE-II; COLORECTAL-CANCER; NSABP C-07; LEUCOVORIN; CHEMOTHERAPY; IRINOTECAN;
D O I：
10.1200/JCO.2012.44.1949
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3325 / 3327
页数：3
相关论文
共 31 条
  • [1] Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer
    Abrams, Thomas A.
    Brightly, Rick
    Mao, Jianbin
    Kirkner, Gregory
    Meyerhardt, Jeffrey A.
    Schrag, Deborah
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3255 - 3262
  • [2] Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial
    Alberts, Steven R.
    Sargent, Daniel J.
    Nair, Suresh
    Mahoney, Michelle R.
    Mooney, Margaret
    Thibodeau, Stephen N.
    Smyrk, Thomas C.
    Sinicrope, Frank A.
    Chan, Emily
    Gill, Sharlene
    Kahlenberg, Morton S.
    Shields, Anthony F.
    Quesenberry, James T.
    Webb, Thomas A.
    Farr, Gist H., Jr.
    Pockaj, Barbara A.
    Grothey, Axel
    Goldberg, Richard M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13): : 1383 - 1393
  • [3] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
    Allegra, Carmen J.
    Yothers, Greg
    O'Connell, Michael J.
    Sharif, Saima
    Petrelli, Nicholas J.
    Colangelo, Linda H.
    Atkins, James N.
    Seay, Thomas E.
    Fehrenbacher, Louis
    Goldberg, Richard M.
    O'Reilly, Seamus
    Chu, Luis
    Azar, Catherine A.
    Lopa, Samia
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) : 11 - 16
  • [4] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [5] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
    Andre, Thierry
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Bridgewater, John
    Rivera, Fernando
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3109 - 3116
  • [6] Clinical Practice Guidelines in Oncology
    Benson, Al B., III
    Arnoletti, J. Pablo
    Bekaii-Saab, Tanios
    Chan, Emily
    Chen, Yi-Jen
    Choti, Michael A.
    Cooper, Harry S.
    Dilawari, Raza A.
    Engstrom, Paul F.
    Enzinger, Peter C.
    Fleshman, James W., Jr.
    Fuchs, Charles S.
    Grem, Jean L.
    Knol, James A.
    Leong, Lucille A.
    Lin, Edward
    May, Kilian Salerno
    Mulcahy, Mary F.
    Murphy, Kate
    Rohren, Eric
    Ryan, David P.
    Saltz, Leonard
    Sharma, Sunil
    Shibata, David
    Skibber, John M.
    Small, William, Jr.
    Sofocleous, Constantinos T.
    Venook, Alan P.
    Willett, Christopher
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (11): : 1238 - 1290
  • [7] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [8] Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set
    de Gramont, Aimery
    Hubbard, Joleen
    Shi, Qian
    O'Connell, Michael J.
    Buyse, Marc
    Benedetti, Jacqueline
    Bot, Brian
    O'Callaghan, Chris
    Yothers, Greg
    Goldberg, Richard M.
    Blanke, Charles D.
    Benson, Al
    Deng, Qiqi
    Alberts, Steven R.
    Andre, Thierry
    Wolmark, Norman
    Grothey, Axel
    Sargent, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 460 - 465
  • [9] Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
    Grothey, Axel
    Nikcevich, Daniel A.
    Sloan, Jeff A.
    Kugler, John W.
    Silberstein, Peter T.
    Dentchev, Todor
    Wender, Donald B.
    Novotny, Paul J.
    Chitaley, Umesh
    Alberts, Steven R.
    Loprinzi, Charles L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 421 - 427
  • [10] Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
    Haller, Daniel G.
    Tabernero, Josep
    Maroun, Jean
    de Braud, Filippo
    Price, Timothy
    Van Cutsem, Eric
    Hill, Mark
    Gilberg, Frank
    Rittweger, Karen
    Schmoll, Hans-Joachim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) : 1465 - 1471
1234